Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione

Patent Citations (108)

Non-Patent Literature (266)

• Carstensen, 1995, Drug Stability: Principles & Practice, 2nd. ed., Marcel Dekker, New York, NY pp. 379-380.Applicant
• Corral et al., 1999, “Immunomodulation by thalidomide and thalidomide analogues,” Ann. Rheum. Dis. 58(Suppl 1):I107-113.Applicant
• Craig et al., 1967, “Potential anticancer agents. III. 2-phthalimidoaldehydes and derivatives,” Potential Anticancer Agents III 10:1071-1073.Applicant
• D'Amato et al., 2001, “Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma,” Semin. Oncol. 28:597-601.Applicant
• D'Amato et al., 1994, “Thalidomide is an Inhibitor of Angiogenesis”, Proc. Natl. Acad. Sci. 91:4082-4085.Applicant
• De et al., 1976, “Hansch analysis for some antineoplastic glutarimides,” J. Indian Chem. Soc. I.III: 825-826.Applicant
• De et al., 1976, “Possible antineoplastic agents: III. Synthesis of 6-alkyl-2-[4′-methoxyphthalimido] and 6-alkyl-3-[3′-4′-dimethoxyphenyl] glutarimides,” J. Indian Chem. Soc. I.III:1122-1125.Applicant
• Dredge et al., 2002, “Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects,” Br. J. Cancer 87(10):1166-1172.Applicant
• Folkman et al., 1983, “Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone,” Science 221(4612):719-725.Applicant
• Gershbein, 1991, “The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas,” Cancer Letters 60: 129-133.Applicant
• Grabstald et al., 1965, “Clinical experiences with thalidomide in patients with cancer,” Clinical Pharmacology and Therapeutics 6:298-302.Applicant
• Lentzsch et al., 2003, “Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo,” Leukemia 17(1):41-44.Applicant
• Lentzsch et al., 2002, “S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice”, Cancer Research 62:2300-2305.Applicant
• Miyachi et al., 1997, “Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity,” J. Med. Chem. 40:2858-2865.Applicant
• Muller et al., 1999, “Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production,” Bioorg. Med. Chem. Lett. 9(11):1625-1630.Applicant
• Muller et al., 1998, “Thalidomide analogs and PDE4 inhibition,” Bioorg. Med. Chem. Lett. 8(19):2669-2674.Applicant
• Muller et al., 1996, “Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity,” J. Med. Chem. 39(17):3238-3240.Applicant
• Olson et al., 1965, “Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer,” Clinical Pharmacology and Therapeutics 6(3):292-297.Applicant
• Penichet et al., 2001, “Antibody-cytokine fusion proteins or the therapy of cancer,” J. Immunol. Methods 248(1-2):91-101.Applicant
• Physician's Desk Reference, 2002, 56th ed., pp. 1755-1760.Applicant
• Raza et al., 2001, “Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplatic syndromes,” Blood 98(4):958-965.Applicant
• Shah et al., 1999, “Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis,” J. Med. Chem. 42:3014-3017.Applicant
• Shibata et al., 1995, “N-alkylphthalimides: structural requirement of thalidomidal action on 12-0-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor a production by human leukemia HL-60 cells,” Chem. Pharm. Bull. 43(1):177-179.Applicant
• Shimazawa et al., 1999, “Antiangioneci activity of tumor necrosis factor-alpha production regulators derived from thalidomide,” Biol. Pharm. Bull. 22(2):224-226.Applicant
• Rubin et al, “Principles of Cancer Treatment-1”, 12 ONCO IV 1, May 2003.Applicant
• Wilen et al., 1977, Tetrahedron 33:2725.Applicant
• Wilen, 1972, Tables of Resolving Agents and Optical Resolutions, E.L. Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN pp. 268.Applicant
• Wolff ed., 1995, Burger's Medicinal Chemistry and Drug Discovery, 5th ed., pp. 172-178, 949-982.Applicant
• N. Ake Jonnson, 1972, “Chemical Structure and Teratogenic Properties,” Acta Pham., pp. 521-542.Applicant
• Alexanian et al., 2004, “VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma,” Am. Soc. Hematol. 46th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #210.Applicant
• Anderson, 2000, “Thalidomide: Therapeutic potential in hematologic malignancies,” Seminars in Hematology 37(I Supp 3): 1-4.Applicant
• Attal et al., 2004, “Maintenance treatment with thalidomide after autologous transplantation for myeloma: First analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02),” Am. Soc. Hematol. 46th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #535.Applicant
• Bernardeschi et al., 2003, J. Exp. Clin. Cancer Res. 22(4):129-133.Applicant
• Corral et al., 1999, “Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha,” J. Immunol. 163(1):380-386.Applicant
• Davies et al., 2001, “Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma,” Blood 98(1):210-216.Applicant
• Dimopoulos et al., 2004, “Primary treatment with puilsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma ≧75 years of age,” Am. Soc. Hematol. 46th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #1482.Applicant
• Eisen et al., 2000, “Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer,” Br. J. Cancer 82(4):812-817.Applicant
• Fakhouri et al., 2004, “Thalidomide in patients with multiple myeloma and renal failure,” Br. J. Haematol. 125:90-102.Applicant
• Fenk et al., 2005, “Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma,” Leukemia 19(1):156-159.Applicant
• Gupta et al., 2001, “Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications,” Leukemia 15(12):1950-1961.Applicant
• Haslett et al., 2003, “Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T Cells in vitro,” J. Infect. Dis. 187(6):946-955.Applicant
• Hideshima et al., 2000, “Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy,” Blood 96(9):2943-2950.Applicant
• Offidani et al., 2003, Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica, Dec. 2003;88(12):1432-1433.Applicant
• Palumbo et al., 2004, “A prospective randomized trial of oral melphalan prednisone, thalidomide (MPT) vs. oral melphalan, prednisone (MP): An interim analysis,” Am. Soc. Hematol. 46th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #207.Applicant
• Raje et al., 1999, “Thalidomide—a revival story,” N. Engl. J. Med. 341(21):1606-1609.Applicant
• Rajkumar et al., 2004, “Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): Results of a phase III trial coordinated by the Eastern Cooperative Oncology Group,” Am. Soc. Hematol. 46th Ann. Meeting Dec. 4-7, 2004, San Diego, CA Abstract #205.Applicant
• Rajkumar et al., 2000, “Prognostic value of bone marrow angiogenesis in multiple myeloma,” Clin. Cancer Res. 6(8):3111-3116.Applicant
• Ribatti et al., 1999, “Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma,” Br. J. Cancer 79(3-4):451-455.Applicant
• Singhal et al., 1999, Antitumor activity of thalidomide in refractory multiple myeloma, N. Engl. J. Med. 341(21):1565-1571.Applicant
• Steins et al., 2002, “Efficacy and safety of thalidomide in patients with acute myeloid leukemia,” Blood 99(3):834-839.Applicant
• Vacca et al., 1999, “Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma,” Blood 93(9):3064-3073.Applicant
• Wohrer et al., 2004, “Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone—a case report,” Hematol. J. 5(4):361-363.Applicant
• Bach, 1963, “Thalidomide in Cancer Chemotherapy,” The Lancet, No. 1271, p. 71.Applicant
• Bach, 1963, “Studies on the Possible Anti-Neoplastic Effect of Thalidomide,” Acta Pathologica Et Microbiologica Scandinavica 59:491-499.Applicant
• Chaundhry, 1966, Cancer Research, “Effect of Prednisolone and Thalidomide on Induced Submandibular Gland Tumors in Hamster,” 26(part 1)1884-86.Applicant
• DiPaolo, 1963, “Effect of Thalidomide on a Variety of Transplantable Tumors,” Cancer Chemotherapy Reports No. 29, p. 99-102.Applicant
• DiPaolo, 1963, “In vitro Test Systems for Cancer Chemotherapy, II. Correlation of in vitro Inhibition of Dehydrogenase and Growth with in vivo Inhibition of Ehrlich Asoites Tumor,” Proceedings of the Society for Experimental Biology & Medicine, 114:384-387.Applicant
• DiPaolo, 1964, “Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro” Science 144:1583.Applicant
• Mauad, 1963, “Clinical Improvements Obtained in Advanced Caner Patients with Treatment with Thalidomide Associated with Hormones,” Anais Paulistas de Medicina e Cirurgia 86:13-40.Applicant
• Roe and Mitchley, 1963, “Thalidomide and Neoplasia” Nature 200:1016-1017.Applicant
• Liu et al., “Phase I study of CC-5013 (Revimid), a thalidomide derivative, in patients with refractory metastatic cancer,” American Society of Clinical Oncology, Abstract #927, 2003.Applicant
• Zangari et al., “Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT),” American Society of Hematology, Abstract #3226, 2001.Applicant
• Zeldis et al., “Update on the evolution of the 1MiD™,” International Society for Biological Therapy of Cancer, Oral Abstract, 2003.Applicant
• Anderson, “Moving disease biology from the laboratory to the clinic,” Seminars in Oncology, 2002 29:17-20.Applicant
• Barlogie et al., “Total Therapy II (TT11) for newly diagnosed multiple myeloma (MM): preliminary data on feasibility and efficacy in the first 231 enrolled patients; comparison with predecessor trial total therapy I ((TT1) (N=231),” Blood, Abstract # 2857, Dec. 7-11, 2001, American Society of Hematology.Applicant
• Barlogie et al., “High-dose therapy immunomodulatory drugs in multiple myeloma,” Seminars in Oncology, 2002, 29 (6):26-33.Applicant
• Barlogie et al., “Introduction: Thalidomide and the 1MiDs in multiple myeloma,” Seminars in Hematology, 2003, 40 (4):1-2.Applicant
• Barlogie, “Thalidomide and CC-5013 in Multiple Myeloma: The University of Arkansas experience,” Seminars in Hematology, 2003, 40 (4):33-38.Applicant
• Bartlett et al., “The evolution of thalidomide and its 1MiD derivatives as anticancer agents,” Nature Reviews Cancer, 2004, 4 (4):1-9.Applicant
• Bartlett et al., “Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers,” British Journal of Cancer, 2004, 90:955-961.Applicant
• Battegay, “Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects,” J. Mol. Med., 1995, 73:333-346.Applicant
• Baz et al., “Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and revlimid (R) (DVd-R) results in a high response rate in patients with refractory multiple myeloma (RMM),” Blood, Abstract #2559, American Society of Hematology, Dec. 10-13, 2005.Applicant
• Brennen et al., “Thalidomide and analogues: current proposed mechanisms and therapeutic usage,” Clinical Prostate Cancer, 2004, 3 (1):54-61.Applicant
• Celgene Corporation, “Celgene advances immunomodulatory drug (1MiD™) clinical program,” Press Release, Feb. 2000.Applicant
• Celgene Corporation, “Initial Phase I solid tumor data on Celgene's lead 1MiD™, Revimid™,” Press Release, Jun. 2001.Applicant
• Celgene Corporation, “Celgene Corporation Receives orphan drug designation for Revimid™ for multiple myeloma,” Press Release, Oct. 2001.Applicant
• Celgene Corporation, “Celgene Corporation announces third quarter results. Thalomid® (thalidomide) sales increase 24%. Prescriptions up 50%. Enhanced S.T.E.P.S.® launched. Pilot d-MPH data presented,” Press Release, Oct. 2001.Applicant
• Celgene Corporation, “Celgene expands clinical development program for Revimid™. Five additional trials of Revimid initiated in hematological and solid tumor cancers,” Press Release, Jun. 2002.Applicant
• Celgene Corporation, “Celgene Corporation announces third quarter results. Thalomid® (thalidomide) revenue increases 41% to $30.5 million. Pivotal programs for Thalomid and Revimid™ finalized. Peer-reviewed publications of Thalomid and Revimid data. First JNK inhibitor advanced to Phase I clinical trial,” Press Release, Oct. 2002.Applicant
• Celgene Corporation, “Blood reports Revimid™ has anti-tumor activity in patients with relapsed and refractory multiple myeloma,” Press Release, Nov. 1, 2002.Applicant
• Celgene Corporation, “Celgene provides update on clinical pipeline. Celgene Announces first target indication for ACTIMID™, CC-8490. SelCID™ program to advance based on results from Phase I/II trial of CC-1088. First JNK inhibitor successfully completes phase I trial,” Press Release, Jan. 2003.Applicant
• Celgene Corporation, “Celgene Corporation announces fourth quarter and full year results for 2002,” Press Release, Jan. 2003.Applicant
• Celgene Corporation, “Celgene receives fast track status from FDA for Revimid™ in multiple myloma,” Press Release, Feb. 2003.Applicant
• Celgene Corporation, “Celgene receives fast track status from FDA for Revimid™ in myelodysplastic sydromes,” Press Release, Apr. 2003.Applicant
• Celgene Corporation, “New Revimid™ clinical data shows potential as novel approach to treating myelodysplastic syndromes (MDS),” Press Release, May 2003.Applicant
• Celgene Corporation, “Celgene corporation reports strong operating performance in second quarter as total sales increase 100 percent and profits rise,” Press Release, Jul. 2003.Applicant
• Celgene Corporation, “Celgene corporation reports record operating performance in third quarter as total revenue increases 117% and profits rise,” Press Release, Oct. 2003.Applicant
• Celgene Corporation, “Celgene corporation advances ACTIMID™ (CC-4047) into phase II trial for prostate cancer,” Press Release, Oct. 2003.Applicant
• Celgene Corporation, “Additional clinical data presented on Revimid™ in myelodysplastic sydromes at the American Society of Hematology 45th annual meeting,” Press Release, Dec. 2003.Applicant
• Celgene Corporation, “Celgene corporation reviews 2003 achievements and announces 2004 financial outlook,” Press Release, Jan. 2004.Applicant
• Celgene Corporation, “Revlimid™ receives orphan drug designation from the European commission for multiple myeloma,” Press Release, Feb. 2004.Applicant
• Celgene Corporation, “Revlimid™ receives orphan drug designation from the European commission for myelodysplastic sydromes,” Press Release, Mar. 2004.Applicant
• Celgene Corporation, “Celgene corporation reports record operating performance in first quarter with strong revenue growth and profits,” Press Release, Apr. 2004.Applicant
• Celgene Corporation, “Celgene announces plans to stop phase III trials in melanoma due to lack of efficacy,” Press Release, Apr. 2004.Applicant
• Dalgleish, et al., “New thalidomide analogues; anti-cancer, anti-angiogenic and immunostimulatory,” British Journal of Cancer, 2001, 85 (1)25.Applicant
• Dalgleish et al., “Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma,” British Journal of Cancer, 2003, 88(Suppl I), S25-S54.Applicant
• Davies et al., “Thalidomide (Thal) and immunomodulatory derivatives (IMiDs) augment natural killer (NK) cell cytotoxicity in multiple myeloma(MM)),” Abstract # 3617, American Society of Hematology, Dec. 1-5, 2000.Applicant
• Davies et al., “Thalidomide (Thal) and immunomodulatory derisatives (IMiDs) augment natural killer (NK) cell cytotoxicity in multiple myeloma ˜MM),” Abstract # P222, VIIIth International Myeloma Workshop, May 4-8, 2001.Applicant
• Dibbs et al., “Thalidomide and thalidomide analogs suppress TNFα secretion by myocytes,” Abstract # 1284, Circulation, 1998.Applicant
• Dimopoulos et al., “Results of thalidomide and IMIDs in multiple myeloma,”, Abstract # P12.1.4, International Multiple Myeloma Workshop, May 23-27, 2003.Applicant
• Dimopoulos et al., “Treatment of plasma cell dyscrasias with thalidomide and its derivatives,” Journal of Clinical Oncology, Dec. 1, 2003, 21 (23)4444-4454.Applicant
• Dimopoulos et al., “Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 Study (MM-010),”, Abstract # 6, American Society of Hematology, Dec. 10-13, 2005.Applicant
• Dredge et al., A costimulatory thalidomide analog enhances the partial anti-tumor immunity of an autologous vaccination in a model of colorectal cancer, Abstract # 491, American Association for Cancer Research, Apr. 6-10, 2002.Applicant
• Dredge et al., “Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy,” Cancer Immunol. Immunother., 2002, 51:521-531.Applicant
• Dredge et al., “Immunological effects of thalidomide and its chemical and functional analogs,” Critical Reviews in Immunology, 2002, 22 (5&6):425-437.Applicant
• Dredge et al., “Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity,” The Journal of Immunology, 2002, 168:4914-4919.Applicant
• Dredge et al., “Recent developments in antiangiogenic therapy,” Expert Opin. Biol. Ther., 2002, 2 (8):953-966.Applicant
• Dredge et al., “Angiogenesis inhibitors in cancer therapy,” Current Opinion in Investigational Drugs, 2003, 4 (6):667-674.Applicant
• Dredge et al., “Thalidomide analogs as emerging anti-cancer drugs,” Anti-Cancer Drugs, 2003, 14:331-335.Applicant
• Fickentscher et al., “Stereochemical properties and teratogenic activity of some tetrahydrophthalimides,” Molecular Pharmacology, 1976, 13:133-141.Applicant
• Figg et al., “Inhibition of angiogenesis: treatment options for patients with metastic prostate cancer,” Investigational New Drugs, 2002, 20(2):183-194.Applicant
• Galustian et al., “Thalidomide-derived immunomodulatory drugs as therapeutic agents,” Expert Opin. Biol. Ther., 2004, 4 (12):1-8.Applicant
• Glaspy et al., “The potential role of thalidomide and thalidomide analogs in melanoma,” Clinical Advances in Hematology & Oncology, 2004, 1-7.Applicant
• Gupta et al., “Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications,” Leukemia, 2001, 15:1950-1961.Applicant
• Hayashi et al., “Mechanisms whereby immunomodulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity,” Blood, Abstract # 3219, Dec. 6-10, 2002, American Society of Hematology.Applicant
• He, W., et al., 1993, Abstract of papers, 206th American Chemical Society, Chicago, IL; Med. Chem., paper 216.Applicant
• Helm et al., “Comparative teratological investigation of compounds of structurally and pharmacologically related to thalidomide,” Arzneimittel Forschung/Drug Research, 1981, 31 (1)941-949.Applicant
• Hernandez-Illizaliturr et al., “Addition of immunomodulatory drugs CC5013 or CC4047 to rituximab enhances anti-tumor activity in a severe combined immunodeficiency (SCID) mouse lymphoma model,” Abstract # 235, American Society of Hematology, Dec. 6-9, 2003.Applicant
• Hideshima et al., “Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy,” Blood, 2000, 96:2943-2950, American Society of Hematology.Applicant
• Hideshima et al., “Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy,” Abstract 1313, American Society of Hematology, Dec. 1-5, 2000.Applicant
• Hunt et al., “Markers of endothelial and haemostatic activation in the use of CC-4047, a structural analogue of thalidamide, in relapsed myeloma,” Blood, Abstract # 3216, Dec. 6-10, 2002, American Society of Hematology.Applicant
• Hussein et al., “Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and Revlimid (DVd-R) a phase I/II trial in advanced relapsed/refractory multiple myeloma (Rmm) patients,” Blood, Abstract #208, American Society of Hematology, Dec. 4-7, 2004.Applicant
• Hwu et al., “Thalidomide and its analogues in the treatment of metastatic melanoma,” Chemotherapy Foundation Symposium, Abstract #44, 2002.Applicant
• Kyle, “Current therapy of multiple myeloma,” Internal Medicine, 2002, 41 (3)175-180.Applicant
• Kyle et al., “Multiple myeloma,” New England Journal of Medicine, 2004, 351:1860-1873.Applicant
• Leblanc et al., “Immunomodulatory drug costimulates T cells via the B7-CD28 pathway,” Blood, 2004, 103:1787-1790, American Society of Hematology.Applicant
• Lentzsch et al., “In vivo activity of thalidomide and immunomodulatory drugs against multiple myeloma,” VIIIth International Myeloma Workshop, Abstract #P225, May 4-8, 2001.Applicant
• Lentzsch et al., “Immunomodulatory derivative of thalidomide (1MiD CC-4047) determine the lineage commitment of hematopoietic progenitors by down regulation of GATA-1 and modulation of cytokine secretion,” Abstract # 3073, American Society of Hematology, Dec. 6-9, 2003.Applicant
• Lentzsch et al., “Immunomodulatory derivative of thalidomide (IMiD CC-4047) down regulates CAAT/enhancer-binding protein β(C/EBP β) in multiple myeloma (MM),” Abstract # 3456, American Society of Hematology, Dec. 6-9, 2003.Applicant
• Luzzio et al., “Thalidomide analogues: derivatives of an orphan drug with diverse biological activity,” Expert Opin. Ther. Patents, 2004, 14 (2):215-229.Applicant
• Man et al., “α- Fluoro-substituted thalidomide analogues,” Bioorganic & Medicinal Chemistry Letters 13, 2003, 3415-3417.Applicant
• Marriott et al., “Immunotherapeutic and antitumour potential of thalidomide analogues,” Expert Opin. Biol. Ther., 2001, 1 (4):1-8.Applicant
• Marriott et al., “New thalidomide analogues; anti-cancer, anti-angiogenic and immunostimulatory,” British Journal of Cancer, 85:25, Jul. 6, 2001.Applicant
• Marriott et al., “Thalidomide and its analogues have distinct and opposing effects on TNF-α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells,” Clin. Exp. Immunol., 2002, 130:75-84.Applicant
• Marriott et al., “A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins1,” Cancer Research, 2003, 63:593-599.Applicant
• Marriott et al., “Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents,” Current Drug Targets—Immune, Endocrine & Metabolic Disorders, 2003, 3:181-186.Applicant
• Masellis et al., “Changes in gene expression in bone marrow mesenchymal progenitor cells as a consequence of IMiD therapy in multiple myeloma patients,” Blood, Abstract # 1548, Dec. 7-11, 2001, American Society of Hematology.Applicant
• McCarty, “Thalidomide may mpede cell migration in primates by down-regulating integrin β-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis,” Medical Hypotheses, 1997, 49:123-131.Applicant
• Mitsiades et al., “Apoptic signaling induced by immunomodulatory thalidomide analogs (Imids) in human multiple myeloma cells: therapeutic implications,” Abstract, # 3224, Dec. 7-11, 2001, American Society of Hematology.Applicant
• Mitsiades et al., “Apoptic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications,” Blood, 2002, 99:4525-4530, American Society of Hematology.Applicant
• Mitsiades et al., “CC-5013 Celgene,” Current Opinion in Investigational Drugs, 2004, 5 (6):635-647.Applicant
• Moutouh et al., “Novel immunomodulatory drugs (IMiDs®): A potential, new therapy for β-hemoglobinopathies,” Abstract # 3740, American Society of Hematology, Dec. 4-7, 2004.Applicant
• Patten et al., “The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047),” Abstract # 1640, American Society of Hematology, Dec. 6-9, 2003.Applicant
• Payvandi et al., “Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines,” Blood, Abstract #2487, Dec. 1-5, 2000, American Society of Hematology.Applicant
• Payvandi et al., “The thalidomide analogs IMiDs enhance expression of CD69 stimulatory receptor on natural killer cells,” Abstract # 1793, American Association for Cancer Research, Mar. 24-28, 2001.Applicant
• Payvandi et al., “Thaliomide analogs IMiDs inhibit expression of cyclooxygenase-2 in multiple myeloma cell line and LPS stimulated PBMCs,” Blood, Abstract # 2689, Dec. 7-11, 2001, American Society of Hematology.Applicant
• Payvandi et al., “Thalidomide and IMiDS inhibit microvessel formation from human arterial rings in the absence of human liver microsomes,” Blood, Abstract # 5046, Dec. 6-10, 2002, American Society of Hematology.Applicant
• Payvandi et al., “CC-5013 inhibits the expression of adhesion molecules ICAM-I and CD44 and prevents metastasis of B16 F10 mouse melanoma cells in an animal model,” American Society of Clinical Oncology, Abstract # 992, 2003.Applicant
• Payvandi et al., “Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner,” Cellular Immunology, 2004, 81-88.Applicant
• Raje et al., “Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma,” Blood, Dec. 15, 2004, 104 (13)4188-4193.Applicant
• Rajkumar et al., “Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma,” Blood, Dec. 15, 2005, 106 (13)4050-4053.Applicant
• Richardson et al., “A Phase I study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM),” Blood, Abstract #3225, Dec. 7-11, 2001, American Society of Hematology.Applicant
• Richardson et al., “Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma,” Blood, 2002 100:3063-3067, American Society of Hematology.Applicant
• Richardson et al., “A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for thc treatment of relapsed or refractory multiple myeloma (MM),” Blood, Abstract # 825, American Society of Hematology, Dec. 6-9, 2003.Applicant
• Richardson et al., “Immunodulatory analogs of thalidomide: an emerging new therapy in myeloma,” Journal of Clinical Oncology, 2004, 22(16) 3212-3214.Applicant
• Richardson et al., “A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma: preliminary results,” 10th International Myeloma Workshop, Apr. 10-14, 2005.Applicant
• Richardson et al., “Novel biological therapies for the treatment of multiple myeloma,” Best Practice & Research Clinical Haematology, 2005, 18(4):619-634.Applicant
• Richardson et al., “A phase 1 trial of lenalidomide (REVLIMID®) with bortezomib (VELCADE®) in relapsed and refractory multiple myeloma,” Blood, Abstract # 365, American Society of Hematology, Dec. 10-13, 2005.Applicant
• Rubin et al., “Principles of cancer treatment-1,” 2003, 12 ONCO IV 1.Applicant
• Schafer et al., “Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs,” Journal of Pharmacology and Experimental Therapeutics, 2003, 305(3)1222-1232.Applicant
• Schey et al., “A phase 1 study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma,” Journal of Clinical Oncology, 2004, 22 (16):1-8.Applicant
• Schey et al., “A phase 1 study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma,” International Society for Experimental Hematology, Abstract #248, 2002.Applicant
• Shaughnessy et al., “Global gene expression analysis shows loss of C-MYC and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD,” Abstract # 2485, The American Society of Hematology, Dec. 1-5, 2000.Applicant
• Shire et al., “TNF-α inhibitors and rheumatoid arthritis,” Exp. Opin. Ther. Patents, 1998, 8 (5):531-544.Applicant
• Sorbera et al., “CC-5013. Treatment of multiple myeloma. Treatment of Melanoma. Treatment of myelodysplastic syndrome. Angiogenesis inhibitor. TNF-α production inhibitor,” Drugs of the Future, 2003, 28(5):425-431.Applicant
• Streetly et al., “Thalidomide analogue CC-4047 is effective in the treatment of patients with relapsed and refractory multiple myeloma (MM) and induces T-cell activation and IL-12 production,” Abstract #367, International Multiple Myeloma Workshop, May 23-27, 2003.Applicant
• Streetly et al., “Changes in neutrophil phenotype following the administration of CC-4047 (Actimid) to patients with multiple myeloma,” Abstract # 2543, American Society of Hematology, Dec. 6-9, 2003.Applicant
• Streetly et al., “An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma,” Abstract #829, American Society of Hematology, Dec. 6-9, 2003.Applicant
• Teo et al., “A phase I, single-blind, placebo-controlled, ascending single oral dose, safety, tolerability and pharmacokinetic study of CDC-501, a novel immunomodulatory-oncologic agent, in healthy male subjects with a comparison of fed and fasted,” Clinical Pharmacology and Therapeutics, 2002, 71 (2)93.Applicant
• Teo et al., “Chiral inversion of the second generation IMiD™ CC-4047 (ACTIMID™) in human plasma and phosphate-buffered saline,” Chirality, 2003, 15:348-351.Applicant
• Thertulien et al., “Hybrid MEL/DT PACE autotransplant regimen for Multiple Myeloma (MM)—safety and efficacy data in pilot study of 15 patients,” Blood, Abstract # 2869, American Society of Hematology, Dec. 7-11, 2001.Applicant
• Tohnya et al., “A phase I study of oral CC-5013 (lenalidomide, Revlimid™), a thalidomide derivative, in patients with refractory metastatic cancer,” Clinical Prostate Cancer, 2004, 2:241-243.Applicant
• Tricot et al., “Angiochemotherapy (ACT) for multiple myloma (MM) with DT-PACE results in a high response rate, but in contrast to tandem transplants with melphalan does not affect durable disease control,” Blood, Abstract # 3531, American Society of Hematology, Dec. 7-11, 2001.Applicant
• Tsenova et al., “Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis,” Antimicrobial Agents and Chemotherapy, 2002, 46 (6)1887-1895.Applicant
• Weber, “Lenalidomide (CC-5013, Revlimid™) and other ImiDs,” Abstract # PL.5.02, International Multiple Myeloma Workshop, Apr. 10-14, 2005.Applicant
• Weber et al., “A multicenter, randomized, parallel-group, double-blind, placebo-controlled study of lenalidomide plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma,” Abstract # PO.738, International Multiple Myeloma Workshop, Apr. 10-14, 2005.Applicant
• Ye et al., “Novel IMiD drugs enhance expansion and regulate differentiation of human cord blood CD34+ cells with cytokines,” Blood, Abstract #4099, American Society of Hematology, Dec. 6-10, 2002.Applicant
• Zangari et al., “Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (Pts) treated with thalidomide (Thal): The Arkansas Experience” Blood, Abstract # 681, American Society of Hematology, Dec. 7-11, 2001.Applicant
• Zangari et al., “Revimid 25 mg (Rev 25) ×20 versus 50 mg (REV 50) ×10 q 28 days with bridging of 5 mg ×10 versus 10 mg ×5 as post-transplant salvage therapy for multiple myeloma (MM),” Blood, Abstract # 1642, American Society of Hematology, Dec. 6-9, 2003.Applicant
• Zeldis et al., “Potential new therapeutics for Waldenstrom's macroglobulinemia,” Seminars in Oncology, 2003, 30 (2):275-281.Applicant
• Zhang et al., “CC-5079, a novel microtubule and TNF-a inhibitor with anti-angiogenic and antimetastasis activity,” Abstract # B012, International Conference on Molecular Targets and Cancer Therapeutics, Nov. 17-21, 2003.Applicant
• Anderson, “The Role of Immunomodulatory Drugs in Multiple Myeloma,” Seminars in Hematology, vol. 40, No. 4, Suppl 4, 2003: pp. 23-32.Applicant
• Weber, “Thalidomide and Its Derivatives: New Promise for Multiple Myeloma,” Cancer Control, vol. 10, No. 5, 375-383, 2003.Applicant
• Patt, Yehuda A.; Hassan, Manal M.; Lozano, Richard D.; Ellis, Lee M.; Peterson, J. Andrew; Waugh, Kimberly A.; Durable Clinical Response of Refractory Hepatocellular Carcinoma to Orally Administered Thalidomide. American Journal of Clinical Oncology, 2000.Applicant
• Richardson, Paul; Hideshima, Teru; Anderson, Kenneth; Thalidomide: The Revival of a Drug with Therapeutic Promise in the Treatment of Cancer; Principles & Practice of Oncology, vol. 15, No. 2, 2001.Applicant
• Thomas, Melodie; DOSS, Deborah, Thalidomide Nursing Roundtable Update, Monograph, Sep. 2002.Applicant
• Richardson, Paul; Hideshima, Teru; Anderson, Kenneth; Thalidomide: Emerging Role in Cancer Medicine; Annual Review of Medicine, 2002.Applicant
• Berenson, J.R.; Bergsagel, P. L.; Munshi, N.; Initiation and Maintenance of Multiple Myeloma; Seminars in Hematology, vol. 36, No. 1, Supp. 3, Jan. 1999, pp. 9-13.Applicant
• Gollob, J.A.; Schinpper, C.P.; Orsini, E.; Murphy, E.; Daley, J.F.; Lazo, S.B.; Frank. D.A.; Characterization of a Novel Subset of CD8 T Cells That Expands in patients Receiving Interleukin-12, 02, Am. Soc. For Clin. Investigation, Inc., vol. 102, No. 3, Aug. 1998, pp. 561-575.Applicant
• Cavanagh, L.L.; Barnetson, R.S.; Basten, A.; Halliday, G.M.; Dendritic Epidermal T-Cell Involvement in Induction of CD8+ T-Cell-Mediated Immunity Against an Ultraviolet Radiation-Induced Skin Tumor Int. J. Cancer: 70, 98-105, 1997.Applicant
• Thomas, D.A., Aguayo, A., Estey, E., Albitar, M., O'Brien, S., Giles, F.J., Beran, M., Cortes, J., Zeldis, J., Keating, M.J., Barlogie, B., Kantarjian, H.M., Thalidomide as anti-angiogenesis therapy (rx) in refractory or relapsed leukemia. Abstract #2269, American Society of Hematology, Dec. 3-7, 1999.Applicant
• Barlogie, B., Desikan, R., Munshi, N., Siegel., D., Mehta, J., Singhal, S., Anaissie, E., Single Course D.T. Pace Anti-Angiochemotherapy Effects CR in Plasma Cell Leukemia and Fulminant Multiple Myeloma (MM). Abstract #4180. American Society of Hematology, Dec. 4-9, 1998.Applicant
• Hideshima, T., Chauhan, D., Shima, Y., Noopur, R., Davies, F.E., Tai, Y., Treon, S.P., Lin, B.K., Schlossman, R.L., Richardson, P.G., Gupta, D., Muller, G.W., Stirling, D.I., Anderson, K.C., Thalidome (THAL) and its Analogs Overcome Drug Resistance of Human Multiple Myeloma (MM) Cells to Conventional Therapy. Abstract #1313. American Society of Hematology, Dec. 1-5, 2000.Applicant
• Payvandi, F., Wu, L., Gupta, D., Hideshima, T., Haley, M., Muller, G., Chen, R., Anderson, K.C., Stirling, D., Effects of a Thalidomide Analog on Binding Activity of Transcription Factors and Cell Cycle Progression of Multiple Myeloma Cell Lines. Abstract #2487. American Society of Hematology, Dec. 1-5, 2000.Applicant
• Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y., Lin, B.K., Podar, K., Chauhan, D., Treon, S.P., Gupta, D., Mitsiades, C., Mitsiades, N., Hayashi, T., Richardson, P.G., Schlossman, R.L., Muller, G.W., Stirling, D.I., Anderson, K.C., Thalidomide (THAL) and Immunomodulatory Derivatives (IMiDS) Augment Natural Killer (NK) Cell Cytotocixity in Multiple Myeloma (MM). Abstract #3617. American Society of Hematology, Dec. 1-5, 2000.Applicant
• Hideshima. T., Chauhan, D., Castro, A., Hayashi, T., Mitsiades, C., Mitsiades, N., Akiyama, M., Richardson, P.G., Schlossman, R.L., Adams, J., Anderson, K.C., NF-KB as a Therapeutic Target in Multiple Myeloma (MM), Abstract #1581. American Society of Hematology. Dec. 7-11, 2001.Applicant
• Lentsch, S., Rogers, M., Leblanc, R., Birsner, A., Shah, J., Anderson K., D'Amato R., 3-Amino-Phthalimido-Glutarimide (S-3APG) Inhibits Angiogenesis and Growth in Drug Resistant Multiple Myeloma (MM) in vivo. Abstract #1976, American Society of Hematology, Dec. 7-11, 2001.Applicant
• Park, Y., Kim, S.A., Kim, C.J., Chung, J.H., Mechanism of the Effect of Thalidomide on Human Multiple Myeloma Cells. Abstract #2685. American Society of Clinical Oncology, May 12-17, 2001.Applicant
• Payvandi, F., Wu, E., Haley M., Gupta, D., Zhang, L., Schafer, P., Muller, G.W., Chen, R., Anderson, K.C., Stirling, D., Thalidomide Analogs IMiDS Inhibit Expression of Cyclooxygenase-2 in Multiple Myeloma Cell Line and LPS Stimulated PBMCs. Abstract #2689. American Society of Hematology, Dec. 7-11, 2001.Applicant
• Mitsiades, N., Mitsiades, C., Poulaki V., Akiyama, M., Tai Y., Lin, B., Hayashi, T., Catley, L., Hideshima, T., Chauhan, D., Treon, S.P., Anderson, K.C., Apoptotic Signaling Induced by Immunomodulatory Thalidomide Analogs (Imids) in Human Multiple Myeloma Cells: Therapeutic Implications. Abstract #3224. American Society of Hematology, Dec. 7-11, 2001.Applicant
• Richardson, P.G., Schlossman, R.L., Hideshima, T., Davies, F., Leblanc, R., Catley, L., Doss, D., Kelly, K.A., Mckenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich. R., Ryoo, J., Chauhan, D., Munshi, N., Weller, E., Zeldis, J., Anderson, K.C., A Phase 1 Study of Oral CC5013, an Immunomodulatory Thalidomide (Thal) Derivative, in Patients With Relapsed and Refractory Multiple Myeloma (MM), Abstract #3225. American Society of Hematology, Dec. 7-11, 2001.Applicant
• “Celgene drug promises activity in solid tumors,” Marketletter, Jun. 18, 2001.Applicant
• Meregalli et al., “High-dose dexamethasone as first line therapy of multiple myeloma?”, Recenti Progressi in Medicina, 1998, 89(1):18-20.Applicant
• Official Action in corresponding Canadian Application No. 2,476,983 dated Aug. 21, 2009.Applicant
• List, A., “New Approaches to the Treatment of Myelodysplasia,” The Oncologist, 2002, 7(suppl. 1):39-49.Applicant
• Kurzrock, R., “Myelodysplastic syndrome overview,” Seminars in Hematology (Abstract only), 2002, 39(3)(suppl. 2):18-25 Abstract only.Applicant
• Goerner, et al., “Morbidity and mortality of chronic GVHD after hematopoietic stem cell tranplantation from HLA-identical siblings for patients with aplastic or refractory anemias,” Biology of Blood and Marrow Transplantation (Abstract only), 2002, 8(1):47-56.Applicant
• Thomas, D., “Pilot studies of Thalidomide in Acute Myelogenous Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Disorders,” Seminars in Hematology, 2000, 37(1)(suppl. 3):26-34.Applicant
• Zorat, F. et al., “The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes,” British Journal of Haematology, 2001, 115:881-894.Applicant
• Official Action dated Feb. 10, 2009 in JP Application No. 2004-545192. (English translation provided.).Applicant
• Teramura, M., Men-ekiyokusei Ryouhou, Current Therapy, 2000, 18(5):140-144 (in Japanese).Applicant
• Kon-nichi no Chiryou Shishin, 1997 [Pocket Edition], Igaku Shoin, 1997, 513-514 (in Japanese).Applicant
• Okamoto, T., Kotsuzuiikeisei Shoukougun to Men-eki Ijo, Bessatsu Nihon Rinshou, Syndrome Series for each area, No. 22, Blood Syndromes III, Nihon Rinshou, 213-216 (in Japanese), Oct. 1998.Applicant
• Merck Manual, 17th ed. Japanese version, 1999, 951-952.Applicant
• Notice of Allowance from U.S. Appl. No. 11/096,155 dated Jan. 12, 2010.Applicant
• Rajkumar et al., “Combination therapy with thalidomide plus dexamethasone for newly diagnosed multiple myeloma,” American Society of Hematology, 43rd Annual Meeting, Dec. 7-11, 2001, Abstract #3525.Applicant
• Scheffler et al., “Safety and pharmacokinetics of CDC-501, a novel immunomodulatory-oncologic agent, after single then multiple, oral 100 mg twice daily doses,” American Society Clinical Pharmacology and Therapeutics, Mar. 24-27, 2002, Abstract #WPIII-63.Applicant
• Marriott et al., “Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation,” Br. J. Cancer, 2002, 86(Supp. 1):Abst 6.4.Applicant
• Kast, R.E., “Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities—the role of burproion,” Leukemia Research, 2005, 29:1459-1463.Applicant
• Tsimberidou, A. et al., “Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc:Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatment,” Leukemia Research, 2003, 27:375-380.Applicant
• Dimopoulos, et al., “Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma,” Leukemia, 2009, 1-6.Applicant
• Hideshima, T., et al., “A review of lenalidomide in combination with dexathasone for the treatment of multiple myeloma,” Therapeutics and Clinical Risk Management, 2008, 4(1):129-136.Applicant
• Wang, M., et al., “Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure,” Blood, 2008, 112(12):4445-4451.Applicant
• Gandhi, A., et al., “Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function,” Current Cancer Drug Targets, 2010, 10(1):1-13.Applicant
• Gay, F. et al., “Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients,” Blood, 2010, 115(97):1343-150.Applicant
• Richardson, P. et al., “Thalidomide in multiple mycloma,” Biomed Pharmacother, 2002, 56:115-28.Applicant
• Swartz, G. et al., “Pre-clinical evaluation of ENMD-0995: A thalidomide analog with activity against multiple myeloma and solid tumors,” Cell and Tumor Biology, 2002, 43:181-182, Abstract# 910.Applicant
• Mazucco, R., “Angiogenesis and Anti-angiogenesis Therapeutics,” IDrugs, 2002, 5(4): 320-322.Applicant
• Worker, C., “JP Morgan Hambrecht & Quist—20th Annual Healthcare Conference,” IDrugs, 2002, 5(2):113-116.Applicant
• Treston, A. et al., “Pre-Clinical Evaluation of a Thalidomide Analog with Activity Against Multiple Myeloma and Solid Tumors—ENMD-0995 (S-(−)-3-(3-amino-phthalimido)-glutarimide),” Blood, 2002, 100(11):816a, Abstract #3225.Applicant
• Mazucco, R. and Williams, L., “Immunotherapy, chemoprevention and angiogenesis,” IDrugs, 2002, 5(5):408-411.Applicant
• Fernandes, P., “Anti-Cancer Drug Discovery and Development Summit,” IDrugs, 2002, 5(8):757-764.Applicant
• Notitication letter dated Aug. 30, 2010 from Natco Pharma Limited to Celgene Corporation re: Notification purusant to § 505(j)(2)(B) of the Federal Food, Drug and Cosmetic Act.Applicant
• Complaint for Patent Infringement filed on Oct. 8, 2010 by Celgene Corporation in the U.S. District Court, District of New Jersey against Natco Pharma Limited.Applicant
• Answer to Complaint filed on Nov. 18, 2010 by Natco Pharma Limited in the U.S. District Court, District of New Jersey.Applicant
• Grosshans, E. and Illy, G., “Thalidomide Therapy for Inflammatory Dermatoses,” International Journal of Dermatology, 1984, 23(9):598-602.Applicant
• Krenn, M. et al., “Improvements in Solubility and Stability of Thalidomide upon Complexation with Hydropropyl-β-Cyclodextrin,” Journal of Pharmaceutical Sciences, 1992, 81(7):685-689.Applicant
• Schmahl, H. J. et al., “Pharmacokinetics of the Teratogenic and Nonteratogenic Thalidomide Analogs EM 12 and Supidimide in the Rat and Marmoset Monkey”, in Pharmacokinetics in Teratogenesis, CRC Press, 1987, vol. 1, Ch. 12, pp. 181-192.Applicant
• Schumacher, H. et al., “The Teratogenic Activity of a Thalidomide Analogue, EM12, in Rabbits, Rats, and Monkeys,” Teratology, 1971, 5:233-240.Applicant
• Smith, R. et al., “Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compounds,” in A Symposium on Embryopathic Activity of Drugs, J. & A. Churchill Ltd., 1965, Session 6, pp. 194-209.Applicant
• Sheskin, J. and Sagher, F., “Trials will Thalidomide Derivatives in Leprosy Reactions,” Leprosy Review, 1968, 39(4):203-205.Applicant
• Sheskin, J., “Study with Nine Thalidomide Derivatives in the Lepra Reaction,” Pharmacology and Therapeutics, 1978, 17:82-84.Applicant
• Raje, N. and Anderson, K., “Thalidomide and immunomodulatory drugs as cancer therapy,” Current Opinions in Oncology, 2002, 14:635-640.Applicant
• Kumar, S. et al., “Thalidomide as an anti-cancer agent,” J. Cell. Mod. Med., 2002, 6(2):160-174.Applicant
• Singhal, S. and Mehta, J., “Thalidomide in Cancer,” BioDrugs, 2001, 15(3):163-172.Applicant
• Notice of Opposition to EP 1 505 973 tiled by Synthon B.V. on Nov. 30, 2010.Applicant
• Notice of Opposition to EP 1 505 973 filed by Straw:man Limited on Dec. 1, 2010.Applicant
• Samson, D. et al., “Infusion of Vincristine and Doxoruhicin with Oral Dexamethasone as First-Line Therapy for Multiple Myeloma,” The Lancet, 1989, 334(8668):882-885.Applicant
• Barlogie, B. et al., “Effective Treatment ofAdvanced Multiple Myeloma Refractory to Alkylating Agents,” N. Engl. J. Med., 1984, 310(21):1353-1356.Applicant
• Dimopoulos, M. et al., “Thalidomide and dexamethasone combination for refractory multiple myeloma,” Annals of Oncology, 2001, 12:991-995.Applicant
• Zangari, M., et al., “Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy,” Blood, 2002, 100:1168-1171.Applicant
• List, A. et al., “High Erythropoietic Remitting Activity of the Immunomodulatory Thalidomide Analog, CC5013, in Patients with Myelodysplastic Syndrome (MDS),” Abstract #353, Blood, 2002, 100(11):96a.Applicant
• Mufti, G. et al., “Myelodysplastic Syndrome,” American Society of Hematology, 2003, pp. 176-199.Applicant
• Extracts from drug databases: retrieved from http://www.nextbio.com/b/search/ov/IMiD3%20cpd on Nov. 26, 2010 and http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=216326 on Nov. 26, 2010.Applicant
• Stockdale, 1998, Medicine, Rubenstein and Federman, eds., vol. 3, Ch. 12, Sections IV and X.Applicant
• Office Action mailed Jun. 18, 2008, U.S. Appl. No. 11/325,954.Applicant
• Gamberi et al., “Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)”, presented at 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, Dec. 8-11, 2012, Abstract #4068.Applicant
• Korde et al., “Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients”, presented at 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, Dec. 8-11, 2012, Abstract #732.Applicant
• Kumar et al., “A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexathasone in Patients with Previously Untreated Multiple Myeloma (MM)”, presented at 54th ASH Annual Meeting and Exposition, Atlanta, Georgia. Dec. 8-11, 2012, Abstract #332.Applicant
• Palumbo et al., “Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma”, presented at 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, Dec. 8-11, 2012, Abstract #446.Applicant
• Richardson et al., “A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results”, presented at 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, Dec. 8-11, 2012, Abstract #202.Applicant
• Sacchi et al., “A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma”, presented at 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, Dec. 8-11, 2012, Abstract #1851.Applicant
• Sonneveld et al., “Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM), the HOVON 86 Phase 2 Trial”, presented at 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, Dec. 8-11, 2012, Abstract #1853.Applicant
• Suvannasankha et al., “A Phase I/II Trial Combining High-Dose Lenalidomide with Melphalan and Autologous Transplant for Multiple Myeloma: A Report of the Phase 1 Dose-Finding Study”, presented at 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, Dec. 8-11, 2012, Abstract #3146.Applicant
• Office Action in corresponding CN Application No. 201110256752.0 dated Feb. 8, 2013.Applicant
• Stirling, D., “Thalidomide: A Novel Template for Anticancer Drugs,” Seminars in Oncology, Dec. 2001, 28(6):602-606.Applicant